Kyverna Therapeutics (KYTX) closed at $5.12 on November 11, 2026, up 0.8% from the previous close, on volume of 421,774 shares (30-day average 815,199).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Wed, 11-Nov 1:32 PM ET)
Globe Newswire (Mon, 9-Nov 11:00 AM ET)
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Globe Newswire (Thu, 5-Nov 4:02 PM ET)
Globe Newswire (Fri, 23-Oct 10:30 AM ET)
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Thu, 22-Oct 2:21 PM ET)
Globe Newswire (Wed, 21-Oct 7:15 AM ET)
Globe Newswire (Wed, 7-Oct 8:00 AM ET)
Globe Newswire (Thu, 24-Sep 6:00 AM ET)
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 4:05 PM ET)
Kyverna Therapeutics Secures Scalable Manufacturing for Miv-cel as BLA Submission Nears Completion
Market Chameleon (Mon, 27-Jul 7:46 AM ET)
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Kyverna Therapeutics trades on the NASDAQ stock market under the symbol KYTX.
As of November 11, 2026, KYTX stock price climbed to $5.12 with 421,774 million shares trading.
KYTX has a beta of 2.14, meaning it tends to be more sensitive to market movements. KYTX has a correlation of 0.16 to the broad based SPY ETF.
KYTX has a market cap of $316.64 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that KYTX belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.
KYTX has underperformed the market in the last year with a price return of -26.9% while the SPY ETF gained +12.6%. KYTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.2% and -13.1%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
KYTX support price is $4.82 and resistance is $5.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYTX shares will trade within this expected range on the day.
